ÌÇÐÄÆƽâ°æ

The pharmaceutical segment of Johnson & Johnson was the company’s strongest segment over the last few years, generating nearly 60 billion U.S. dollars in sales globally in 2025. The rise of pharmaceuticals as the company’s leading segment began in 2013, when it was about even with the medical devices and diagnostics segment for the first time. Johnson & Johnson’s third pillar, until 2022, was the consumer health segment. 

Johnson & Johnson company overview

New Jersey-based Johnson & Johnson is a global, diversified healthcare company, with the pharmaceutical business becoming increasingly dominant over time. Within Johnson & Johnson’s pharmaceutical segment, oncology and immunology are the major therapeutic areas. But Johnson & Johnson also has another strong business segment: medical technology. In fact, this segment ranks J&J among the world’s top 10 medical technology companies.

The company’s pharmaceutical segment

Since 2013, the pharmaceutical business has shown significant growth among J&J’s segments. That the company shows particular engagement in this field is also visible by the size of its R&D pipeline, which is one of the largest within the pharma industry, as of 2025. Johnson & Johnson was ranked worldwide based on the number of originated drugs, as of the same year. These developments are comprehensible when considering the company’s share of revenue, which is invested in research and development.